Repositorio de Universidad Autónoma de Chile.
metadata only
Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents
The frequency, complexity and morbidity of neurodegenerative diseases make them a great challenge for nowadays medicine. Most of the treatments currently used for Parkinson's disease – the second most prevalent – are only symptomatic. Therefore, it is urgent to develop drugs that are able to act sim
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?#948596
- Coumarin hybrids as privileged therapeutic scaffolds: biological activities, mechanistic insights, and therapeutic potential.#338586
- Synthesis of N‐Acetyl‐D‐ and ‐L‐Leucine‐ 13 C 6 Tool Compounds in Neurodegenerative Disease#240337
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD#904517
- A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient#811601
Record · ID 948624
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive